Welcome to our dedicated page for Intellia Therapeutics SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Intellia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Intellia Therapeutics's regulatory disclosures and financial reporting.
Intellia Therapeutics (NTLA) reported an insider transaction by its EVP and Chief Scientific Officer. On October 1, 2025, the officer executed a mandatory sell-to-cover of 31 shares of common stock at $17.38 to satisfy tax withholding upon RSU vesting, which the filing notes was not a voluntary trade.
Following the transaction, the officer directly beneficially owned 105,184 shares of Intellia common stock.
Michael P. Dube, Vice President and Chief Accounting Officer of Intellia Therapeutics, Inc. (NTLA), reported a Form 4 disclosing a mandatory tax-withholding sale related to RSU vesting. On 10/01/2025 the reporting person had 1,871 shares sold (transaction code S(1)) at $17.38 per share to satisfy tax withholding obligations arising from RSU vesting. After the sale, the reporting person beneficially owned 55,266 shares. The Form 4 was signed by an attorney-in-fact and dated 10/03/2025. The filing describes the sale as non-volitional and linked solely to tax withholding.
Intellia Therapeutics reported interim clinical data for its in vivo CRISPR gene editing therapy "nex-z" (NTLA-2001) in hereditary transthyretin (ATTR) amyloidosis with polyneuropathy. In an open-label Phase 1 study, a one-time dose at or above 0.3 mg/kg (n=33) produced a mean serum TTR reduction of 92% at 24 months, corresponding to a mean absolute TTR level of 17.3 µg/mL (95% CI 12.5–22.2). Among 12 patients followed to 36 months, mean reduction was 90% with a mean absolute level of 20 µg/mL (95% CI 11.2–28.8).
Clinical measures such as quality-of-life for diabetic neuropathy (QoL-DN) and neurofilament light chain (NfL) trended toward improvement, and 89% of patients showed improvement or stability in PND scores through 24 months versus baseline. The filing also reiterates standard development and collaboration risks, including regulatory and development uncertainties and reliance on partners.
William J. Chase, a director of Intellia Therapeutics, Inc. (NTLA), reported an open-market purchase of 100,000 shares of the issuer's common stock on 08/20/2025. The shares were bought in accordance with the company's trading policies at a weighted average price of $10.03, with transaction prices ranging from $9.97 to $10.04. Following the purchase, the reporting person beneficially owned 134,693 shares. The Form 4 was filed as a single-person report and signed by attorney-in-fact James Basta on 08/22/2025.
Intellia Therapeutics (NTLA) filed an 8-K current report dated 7 Aug 2025 covering two disclosure items.
- Item 2.02 – Results of Operations: The company furnished a press release (Ex. 99.1) announcing Q2 2025 financial results and business updates for the period ended 30 Jun 2025. Specific revenue, EPS or guidance figures are not included in the filing; the information is furnished, not filed, and may be incorporated into future SEC filings only if explicitly referenced.
- Item 5.02 – Executive Change: Executive Vice President & Chief Medical Officer Dr. David Lebwohl, M.D. will retire effective 7 Aug 2026. He will remain CMO until a successor is appointed and stay employed through the retirement date. Upon departure, his equity awards will follow the terms of the company’s Amended & Restated Retirement Policy (filed as Ex. 10.30 to the 2022 10-K).
No other material events, financial tables, or strategic transactions are disclosed in this report.